{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:31:10Z","timestamp":1781188270695,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004410","name":"Scientific and Technological Research Council of Turkey","doi-asserted-by":"publisher","award":["220S454"],"award-info":[{"award-number":["220S454"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology in Vitro"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.tiv.2025.106078","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T15:06:19Z","timestamp":1747321579000},"page":"106078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Selective JAK-1 inhibitor Upadacitinib and peptide PD29 modulate the JAK and TGF-\u03b2\/Smad signaling pathways reducing experimental dermal fibrosis"],"prefix":"10.1016","volume":"107","author":[{"given":"Ay\u015fe","family":"Ko\u00e7ak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cemre","family":"Ural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahide","family":"Cavdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulen","family":"Sario\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcl","family":"Akdo\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merih","family":"Birlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tiv.2025.106078_bb0005","series-title":"StatPearls","article-title":"Systemic Sclerosis [CREST syndrome]","volume":"4","author":"Adigun","year":"2020"},{"issue":"3","key":"10.1016\/j.tiv.2025.106078_bb0010","first-page":"567","article-title":"Janus kinase inhibitor tofacitinib is a potential therapeutic option for refractory eosinophilic fasciitis","volume":"38","author":"Cao","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"10.1016\/j.tiv.2025.106078_bb0015","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.tiv.2025.106078_bb0020","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.tiv.2025.106078_bb0025","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase [JAK] inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tiv.2025.106078_bb0030","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.jid.2019.12.019","article-title":"Jak inhibition prevents bleomycin-induced fibrosis in mice and is effective in patients with morphea","volume":"140","author":"Damsky","year":"2020","journal-title":"J. Invest. Dermatol."},{"issue":"9","key":"10.1016\/j.tiv.2025.106078_bb0035","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/art.34500","article-title":"JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor beta in systemic sclerosis","volume":"64","author":"Dees","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tiv.2025.106078_bb0040","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s40265-019-01211-z","article-title":"Upadacitinib: first approval","volume":"79","author":"Duggan","year":"2019","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.tiv.2025.106078_bb0045","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/art.38702","article-title":"Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct","volume":"66","author":"Herzog","year":"2014","journal-title":"Arthri. & Rheumatol. [Hoboken, N.J.]"},{"issue":"9","key":"10.1016\/j.tiv.2025.106078_bb0050","doi-asserted-by":"crossref","first-page":"859330","DOI":"10.3389\/fmed.2022.859330","article-title":"JAK1\/2 inhibitor Baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis","volume":"6","author":"Hou","year":"2022","journal-title":"Front. Med. [Lausanne]"},{"key":"10.1016\/j.tiv.2025.106078_bb0055","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/rheumatology\/ken179","article-title":"The registry of the German network for systemic SSc: frequency of disease subsets and patterns of organ involvement","volume":"47","author":"Hunzelmann","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.tiv.2025.106078_bb0060","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1111\/bjd.15593","article-title":"Efficacy and tolerance of ruxolitinib in refractory SSctous chronic graft-versus-host disease","volume":"177","author":"Hurabielle","year":"2017","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.tiv.2025.106078_bb0065","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jdcr.2017.12.003","article-title":"Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib","volume":"4","author":"Kim","year":"2018","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.tiv.2025.106078_bb0070","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1515\/tjb-2017-0185","article-title":"Effects of Epigallocatechin-3- gallate [EGCG] on a SSc model of fibrosis","volume":"43","author":"Kocak","year":"2018","journal-title":"Turkish J. Biochem."},{"issue":"1","key":"10.1016\/j.tiv.2025.106078_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5606\/ArchRheumatol.2019.6835","article-title":"Antioxidant effect of epigallocatechin-3-gallate in a bleomycin-induced SSc model","volume":"34","author":"Ko\u00e7ak","year":"2019","journal-title":"Arch. Rheumatol."},{"key":"10.1016\/j.tiv.2025.106078_bb0080","doi-asserted-by":"crossref","DOI":"10.1177\/09603271211065975","article-title":"Protective effects of alpha-lipoic acid on bleomycin-induced skin fibrosis through the repression of NADPH oxidase 4 and TGF-\u03b21\/Smad3 signaling pathways","volume":"41","author":"Kocak","year":"2022","journal-title":"Hum. Exp. Toxicol."},{"issue":"6","key":"10.1016\/j.tiv.2025.106078_bb0085","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/03009742.2017.1387673","article-title":"Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis","volume":"47","author":"Komai","year":"2018","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.tiv.2025.106078_bb0090","article-title":"Janus kinase inhibitors for treatment of morphea and systemic sclerosis: a literature review","volume":"35[6]","author":"McGaugh","year":"2022","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.tiv.2025.106078_bb0095","first-page":"5","article-title":"Peptide PD29 treats bleomycin-induced pulmonary fibrosis by inhibiting the TGF-\u03b2\/smad signaling pathway","volume":"45","author":"Qingbo","year":"2019","journal-title":"Exp. Lung Res."},{"issue":"5","key":"10.1016\/j.tiv.2025.106078_bb0100","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00281-015-0511-7","article-title":"Cytokines in the immunopathology of systemic sclerosis","volume":"37","author":"Raja","year":"2015","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.tiv.2025.106078_bb0105","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.tiv.2025.106078_bb0110","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic JAK inhibitors in dermatology","volume":"10","author":"Solimani","year":"2019","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.tiv.2025.106078_bb0115","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1074\/jbc.M116.773085","article-title":"Transforming growth factor-\u03b2 [TGF-\u03b2] directly activates the JAK1-STAT3 Axis to induce hepatic fibrosis in coordination with the SMAD pathway","volume":"292","author":"Tang","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.tiv.2025.106078_bb0120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.21693\/1933-088X-16.2.61","article-title":"Pulmonary hypertension associated with SSc and connective tissue disease: potential molecular and cellular targets","volume":"16","author":"Trojanowska","year":"2017","journal-title":"Adv. Pulmon. Hypertens."},{"key":"10.1016\/j.tiv.2025.106078_bb0125","first-page":"198","article-title":"Systemic sclerosis: an update","volume":"66","author":"Varga","year":"2008","journal-title":"Bull. NYU Hosp. Jt. Dis."},{"issue":"3","key":"10.1016\/j.tiv.2025.106078_bb0130","first-page":"137","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"J. SSc Related Disord."},{"issue":"3","key":"10.1016\/j.tiv.2025.106078_bb0135","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12016-020-08786-6","article-title":"JAK inhibitors: prospects in connective tissue diseases","volume":"59","author":"You","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.tiv.2025.106078_bb0140","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1093\/rheumatology\/keaa613","article-title":"Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis","volume":"60","author":"You","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.tiv.2025.106078_bb0145","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/annrheumdis-2016-210911","article-title":"JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment","volume":"76","author":"Zhang","year":"2017","journal-title":"Ann. Rheum. Dis."}],"container-title":["Toxicology in Vitro"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233325000724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233325000724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T22:26:31Z","timestamp":1750717591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887233325000724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":29,"alternative-id":["S0887233325000724"],"URL":"https:\/\/doi.org\/10.1016\/j.tiv.2025.106078","relation":{},"ISSN":["0887-2333"],"issn-type":[{"value":"0887-2333","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective JAK-1 inhibitor Upadacitinib and peptide PD29 modulate the JAK and TGF-\u03b2\/Smad signaling pathways reducing experimental dermal fibrosis","name":"articletitle","label":"Article Title"},{"value":"Toxicology in Vitro","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tiv.2025.106078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106078"}}